Gastrointestinal Infections

Patients treated with SER-109 reported a significant improvement in disease-specific health-related quality-of-life, regardless of their clinical outcome.

Utopia Foods, Inc., issued a voluntary recall after their imported Chinese enoki mushrooms tested positive for 2 strains of Listeria monocytogenes involved in an outbreak.

The data may help explain why COVID-19 patients experience dangerous secondary infections.

A Chinese epidemiologist made this claim this weekend as the country gathers for its Lunar New Year celebrations.

Click on the slideshow images to read the full stories featured in this weekly infectious disease recap.

Tibetan Buddhist monks, who meditate regularly, had vastly different gut microbiomes than the non-meditating control group.

Preclinical testing suggests that a newly developed SARS-CoV-2 vaccine could protect against current and future variants.

Fecal microbiota transplant (FMT) is a promising option for patients struggling with CDI recurrences. But how can we ensure the treatment is successful?

A new report finds veterans who took vitamin D supplements were less likely to get COVID-19 and less likely to die within 30 days of infection.

With major updates in HIV, C difficile, hepatitis, yeast infections, and skin and soft tissue infections, this week's Infectious Disease Update has something for everyone.

An easy-to-administer oral biologic kept repeat C difficile infections at bay in a new study.

The US FDA has accepted a Biologics License Application (BLA) for Seres Therapeutics' SER-109, and set a Prescription Drug User Fee Act (PDUFA) action date of April 26, 2023.

C diff patients live in fear of a recurrence, says gastroenterologist Paul Feuerstadt, MD. RBX2660 has entered the FDA pipeline and looks to end this vicious cycle.

A fecal microbiota transplant (FMT) trial was halted early due to clear evidence the treatment was superior to placebo.

The incubation period of the original, wild-type COVID-19 strain was 6.65 days, while the Omicron variant's incubation period has shortened to 3.42 days.

Frequent recurrence of Clostridioides difficile infection drives up financial burdens of the disease and underscores the need to improve access to treatment, infection prevention, and new therapies.

Eric Shaff, president and CEO of Seres Therapeutics, discusses the confirmatory trial findings for SER-109. Seres is filing a Biologics License Application for the recurrent C diff therapy.

SER-109, the investigational oral microbiome therapeutic from Seres, reduced C diff recurrence by 91.3% in at-risk populations.

Seres Therapeutics shared phase 3 trial results demonstrating their investigational microbiome-based therapeutic, SER-109, prevented recurrent C difficile infection (rCDI) in 88% of recipients.

Today, the FDA approved vonoprazan dual and triple therapies, developed by Phathom Pharmaceuticals to treat adults with H. pylori infection.

In a small retrospective study, 7 of 11 patients experienced clinical improvement.

Rising sea temperatures cause Vibrio species, bacteria linked to gastroenteritis, to be identified for the first time in UK waters.

Underweight elderly pneumonia patients were more likely to contract C difficile infection.

For the first time, investigators proved that a higher presence of Clostridioides difficile bacteria and toxins cause a more severe infection.

A global study of C. difficile isolates worldwide found a very high prevalence of the bacteria on shoe soles.

Rare cases of health care–associated meningitis and ventriculitis in adults caused by Candida species are associated with recent bacterial meningitis and broad-spectrum antibiotic use.

Investigators apply guidelines into practical management strategies.

An assessment of the frontline agents show similarities infection cure and recurrence rates at 30 days.

A meta-analysis suggest the 2 first-line C diff therapies provide similar outcomes, yet differ in recurrent infection risk.